Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

Major Program(s) or Research Group(s)

  • Gastrointestinal and Other Cancers
  • Phase 0/I/II Cancer Prevention Clinical Trials Program

Sponsor

National Cancer Institute (NCI)

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT02968810

This randomized phase II trial studies how well simvastatin works in preventing liver cancer
in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth.

Intervention

Placebo Administration, Questionnaire Administration, Simvastatin

Condition

Cirrhosis

Investigators

Marc T Goodman

See list of participating sites